- Home
- CRIS vs LNAI Comparison
CRIS vs LNAI Comparison
Compare CRIS & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRIS | LNAI |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 2.1M |
| IPO Year | 2000 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CRIS | LNAI |
|---|---|---|
| Price | $0.39 | $0.52 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $42.67 | N/A |
| AVG Volume (30 Days) | ★ 223.6K | 99.0K |
| Earning Date | 11-05-2026 | 10-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.57 | 1.85 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,898,000.00 | $51,992.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 31.50 | N/A |
| 52 Week Low | $0.33 | $0.22 |
| 52 Week High | $3,360.00 | $5.02 |
Technical Indicators
Market Signals| Indicator | CRIS | LNAI |
|---|---|---|
| Relative Strength Index (RSI) | 18.80 | 17.84 |
| Support Level | $0.34 | $0.45 |
| Resistance Level | $5.50 | $1.65 |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | 0.77 | -0.05 |
| Stochastic Oscillator | 14.17 | 4.80 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About LNAI Lunai Bioworks Inc.
Lunai Bioworks Inc is an AI-driven biotechnology company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or lifelong cancer remission in some of the deadliest cancers. The Group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. Its reportable segments are BioSymetrics, which derives the maximum revenue, and RENB. Geographically, the Group operates in the United States and Canada.